FORM 4 Check this box if no

longer subject to

may continue. See

Instruction 1(b).

Section 16. Form 4 or Form 5 obligations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type I	Responses)														
Name and Address of Reporting Person * Moran Sean F.				Issuer Name and Ticker or Trading Symbol Corbus Pharmaceuticals Holdings, Inc. [CRBP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
				3. Date of Earliest Transaction (Month/Day/Year) 10/06/2016							X Officer (give title below) Other (specify below) Chief Financial Officer				
(Street) NORWOOD, MA 02062				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ Fo	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person				
(City) (State) (Zip)			(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Secur (Instr. 3)	•]	Date (Month/Day/Year)	any (Month/D	n Da	Year) Code	er. 8)	V Amo	vho respond	Owne Trans (Instr	ed Followin action(s) . 3 and 4)		Ov Fo Di or (I)	wnership of Be Bee rect (D) Ov Indirect (Indirect 4)	neficial vnership astr. 4)
								a currently	m are not re y valid OMB I of, or Benefi ertible securit	control nu	ımber.	inless the	torm display	5	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if	4. Transaction Code		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s)	Form of Derivative Security: Direct (D) or Indirect (I)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option(right to buy)	\$ 8.71	10/06/2016		A		150,000		<u>(1)</u>	10/06/2026	Common Stock	150,000	\$ 0	150,000	D	

Reporting Owners

Describes Occurs Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Moran Sean F. C/O CORBUS PHARMACEUTICALS HOLDINGS, INC 100 RIVER RIDGE DRIVE NORWOOD, MA 02062			Chief Financial Officer			

Signatures

/s/ Sean Moran	10/07/2016
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on October 6, 2017, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on November 6, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.